Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Prolymphocytic Leukemia or Diffuse Large Cell Lymphoma
and you are
between 3 and 80
years old
1
2
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.

Provided treatments

  • Biological: anti-CD19 CAR-NK cells
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02892695. The sponsor of the trial is PersonGen BioTherapeutics (Suzhou) Co., Ltd. and it is looking for 10 volunteers for the current phase.
Official trial title:
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma